enGene Holdings Inc. (NASDAQ:ENGN) Receives Consensus Rating of “Moderate Buy” from Analysts

enGene Holdings Inc. (NASDAQ:ENGN) has earned a consensus recommendation of “Moderate Buy” from the ten ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, seven have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $22.8571.

Several research analysts recently commented on the company. Oppenheimer lowered their target price on enGene from $33.00 to $30.00 and set an “outperform” rating for the company in a research note on Wednesday, March 11th. Guggenheim reiterated a “buy” rating on shares of enGene in a research note on Tuesday, March 10th. Citigroup reissued a “market outperform” rating on shares of enGene in a research report on Monday, January 5th. HC Wainwright restated a “buy” rating and set a $25.00 target price on shares of enGene in a research note on Monday, March 9th. Finally, Wall Street Zen raised shares of enGene from a “sell” rating to a “hold” rating in a report on Saturday, March 14th.

enGene Price Performance

enGene stock opened at $7.07 on Thursday. The company has a quick ratio of 11.75, a current ratio of 11.75 and a debt-to-equity ratio of 0.09. enGene has a 52-week low of $2.65 and a 52-week high of $12.25. The firm has a market cap of $473.62 million, a PE ratio of -3.14 and a beta of -0.29. The company’s 50 day moving average is $9.17 and its two-hundred day moving average is $8.28.

enGene (NASDAQ:ENGN) last posted its quarterly earnings results on Monday, March 9th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.11. On average, research analysts expect that enGene will post -1.56 EPS for the current fiscal year.

Hedge Funds Weigh In On enGene

A number of institutional investors and hedge funds have recently modified their holdings of ENGN. Perceptive Advisors LLC raised its stake in enGene by 179.8% in the fourth quarter. Perceptive Advisors LLC now owns 5,869,076 shares of the company’s stock valued at $52,998,000 after buying an additional 3,771,840 shares in the last quarter. Cormorant Asset Management LP boosted its position in shares of enGene by 72.1% during the 4th quarter. Cormorant Asset Management LP now owns 4,000,000 shares of the company’s stock worth $36,120,000 after acquiring an additional 1,676,405 shares in the last quarter. Blue Owl Capital Holdings LP increased its holdings in shares of enGene by 2.5% in the 4th quarter. Blue Owl Capital Holdings LP now owns 3,360,937 shares of the company’s stock valued at $30,349,000 after acquiring an additional 82,831 shares during the last quarter. Siren L.L.C. purchased a new position in shares of enGene in the 4th quarter valued at about $30,126,000. Finally, Braidwell LP raised its position in shares of enGene by 38.2% during the 4th quarter. Braidwell LP now owns 3,131,319 shares of the company’s stock worth $28,276,000 after acquiring an additional 865,000 shares in the last quarter. Institutional investors and hedge funds own 64.16% of the company’s stock.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.